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ABSTRACT
Objective: The objective of the study was to derive a method
to predict a mean cohort EQ-5D preference-based index
score using published mean statistics of the eight dimension
scores describing the SF-36 health proﬁle.
Methods: Ordinary least square regressions models are
derived using patient level data (n = 6350) collected during
12 clinical studies. The models were compared for goodness
of ﬁt using standard techniques such as variance explained,
the magnitude of errors in predicted values, and the propor-
tion of values within the minimal important difference of
the EQ-5D. Predictive abilities were also compared using
summary statistics from both within-sample subgroups and
published studies.
Results: The models obtained explained more than 56% of
the variance in the EQ-5D scores. The mean predicted
EQ-5D score was correct to within two decimal places for all
models and the absolute error for the individual predicted
values was approximately 0.13. Using summary statistics to
predict within-sample subgroup mean EQ-5D scores, the
mean errors (mean absolute errors) ranged from 0.021 to
0.077 (0.045–0.083). These statistics for the out-of-sample
published data sets ranged from 0.048 to 0.099 (0.064–
0.010).
Conclusions: The models provided researchers with a
mechanism to estimate EQ-5D utility data from published
mean dimension scores. This research is unique in that it uses
mean statistics from published studies to validate the results.
While further research is required to validate the results in
additional health conditions, the algorithms can be used to
derive additional preference-based measures for use in eco-
nomic analyses.
Keywords: EQ-5D, quality of life, SF-36, utility.
Introduction
The quality-adjusted life-year provides a common
metric by which the length of survival is combined
with quality of life (QoL) [1]. It is advocated as the
preferred measure of beneﬁt for economic evaluations
in health care because the results can be used by
decision-makers to prioritize and allocate scarce
health-care resources [2]. To facilitate comparisons
across economic evaluations, policy decision-makers
such as the National Institute of Health and Clinical
Excellence (NICE) recommend a generic preference-
based measure to value health-related quality of life
(HRQoL), and NICE suggests the EQ-5D [2]. Never-
theless, there are three pivotal problems associated
with the current recommendations. First, although
HRQoL literature continues to grow, there are still a
large number of health conditions which cannot be
informed by current evidence. Second, a great deal of
the published data describes HRQoL in terms of health
proﬁles described by either disease-speciﬁc question-
naires or nonpreference-based instruments. Third, the
published preference-based evidence may be derived
from different instruments.
The underlying concepts of the preference-based
indexes may be similar in that a score of one represents
perfect health; zero represents death; and negative
values represent health states considered worse than
death. Nevertheless, fundamental differences, such as
possible range, sensitivity to changes, and different
preference-base weights, can produce wide variances in
the scores produced by the different instruments for the
same health state [3]. The choice of instrument used
could have a substantial impact on policy decisions.
The most frequently used generic HRQoL question-
naires are the SF-36, EQ-5D, and Health Utility Index
(HUI) [4–6]. While all have algorithms, which can be
used to derive general population weighted preference-
based utility indexes, these require access to individual
patient level data [7–9]. In addition, as the number
of preference-based instruments grows, it becomes
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increasingly important to be able to translate from one
index to another. Current literature provides a limited
volume of evidence which can be used to map from
generic questionnaires to alternative preference-based
utility indexes.
Older studies [10–13] concentrated on mapping the
eight SF-36 dimension scores onto the preference-
based HUI2 [7] or the Quality of Well-Being scale [14].
The majority of recent literature presents relationships
between the two SF-12 summary scores [15] and the
HUI3 [16–18] or the EQ-5D [17,19–22]. To our
knowledge, there is no evidence that can be used to
translate the SF-36 dimension scores onto the
preference-based EQ-5D utility index.
The objective of the current study was to derive a
method to predict a mean cohort EQ-5D preference-
based index score using published mean statistics
from the eight dimension scores of the SF-36 health
proﬁle. The results will expand the volume of
published HRQoL evidence that can be used in eco-
nomic evaluations and will facilitate comparability of
the cost-effectiveness ratios generated using different
preference-based measures. This research is unique in
that it is the ﬁrst publication to examine the relation-
ship between the full SF-36 health proﬁle and the
EQ-5D preference-based measure. It is also the ﬁrst
study to validate the results of the research using mean
statistics obtained from the literature.
QoL Instruments
The SF-36
The SF-36 is a generic health questionnaire which con-
tains 36 items [5]. The health proﬁle generated from
the responses covers eight dimensions: physical func-
tioning (PF), role limitations due to physical problems
(RP), role limitations due to emotional problems (RE),
pain (BP), general health perception (GH), vitality
(VT), mental health (MH), and social function (SF).
With each dimension consisting of several items coded
1, 2, or 3, the responses are summed to produce a raw
dimension score (10–30), which is transformed onto
a 0 to 100 scale where 0 and 100 represent severe
impairment and no impairment, respectively.
The EQ-5D
The weights for the EQ-5D preference-based index
used in the current study were obtained from the UK
general public using the time trade-off method [9] The
health states valued were sampled from the 243 pos-
sible health states derived from the three levels (no
problems, some problems, extreme problems/unable)
of each of the ﬁve dimensions (mobility, self-care, usual
activities, pain or discomfort, and anxiety or depres-
sion) covered in the questionnaire. The health state
valuations range from no problems on any dimension
(EQ-5D = 1.0) to most severe impairment on all ﬁve
(EQ-5D = -0.594).
Data Sets
Data Sets Used in the Regressions and
Within-Sample Validation
Individual patient level data (n = 6350) pooled from
12 studies used in previous research in the School of
Health and Related Research was used to explore the
relationship between the dimension scores and the
utility index. Collected during observational studies
and randomized controlled trials, the data covers a
wide range of health conditions including asthma [23],
chest pain [24], healthy older women [25], chronic
obstructive pulmonary disease [26], menopausal
women [27], irritable bowel syndrome [28], trauma
[29], lower back pain [30], leg reconstruction [31], leg
ulcers [32], osteoarthritis [33], and varicose veins [34].
Out-of-Sample Data Sets Used to Validate the Models
Out-of-sample published data sets used to validate the
models were identiﬁed by searching the MEDLINE
database. Studies were retained if they reported the
following statistics: 1) the eight mean for the dimen-
sion scores derived from the SF-36 questionnaire and
2) the mean EQ-5D preference-based utility score
derived from the UK population weights.
Methods
While the objective is to estimate mean EQ-5D scores
using published statistics of the SF-36 health proﬁle,
the regressions are constructed from individual patient
level data.
Statistical Methods
The EQ-5D index is regressed onto the eight health
dimension scores using ordinary least square (OLS)
regressions. The general model is deﬁned as:
EQ x d ri i i= + + + +α β β β ε1 2 3
whereby EQ represents the EQ-5D preference-based
index, x represents the vector of main effects (PF, RP,
BP, GH, VT, SF, RE, MH), d represents the vector of
demographs (age and sex), r represents the vector of
main effect squares, i represents individual respon-
dents, and e represents the stochastic error term of the
regression (the residual).
The models were constructed in STATA (Release 10,
StataCorp., College Station, TX) using backward and
forward eliminations to select signiﬁcant squared
terms. White’s robust standard errors were used to
minimize the likelihood of incorrect inferences from
the statistical tests [35]. Colinearity was assessed using
the variance inﬂation factor (VIF). A suggested rule of
thumb is that correlations must be stronger than |0.70|
to be a problem [36]. Nevertheless, statistical theory
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suggests multicolinearity is only likely to become a
problem if there is perfect correlation between inde-
pendent variables (IVs) in conjunction with a small
number of observations or a large variance in the IVs
[37]. The Cook–Weisenberg and the Shapiro–Wilk test
were used to detect heteroscedasticity and normality in
the residuals, respectively.
Comparing Models
Goodness of ﬁt for models obtained was assessed by
examining the scatter plots of the observed versus the
predicted indexes; the range of predicted values, the
mean error (ME), mean absolute error (MAE), root
mean squared errors (RMSEs), and the number of
errors greater than 0.05 (0.025, 0.01) in absolute
values. The R2 statistic quantiﬁed the explanatory
power of the model, i.e., how much of the variability in
the dependent variable is captured by the predictors
used. The models’ predictive abilities were also com-
pared using standard descriptive statistics (mean, SD,
max, min) for the individual estimates. The minimal
important difference (MID), deﬁned as the smallest
difference in score which patients perceive as beneﬁ-
cial, was also used [38]. Because the objective of the
study was to predict mean preference-based measures
using summary statistics, cohort mean EQ-5D scores
were generated for both within-sample subgroups and
out-of-sample data sets, and the results were compared
using the statistics described above.
Results
Within-Sample Data
Of the total 6350 individual respondents, 40% were
male and the mean age was 52 years. The EQ-5D
preference-based utility score was negatively skewed
(skew = -1.4) with mean 0.71 (SD = 0.28) and median
0.76. The data covered the maximum possible range
(-0.59 to 1) with 1512 (24%) individuals scoring the
maximumvalue (EQ-5D = 1) and 241 (4%) rating their
HRQoL as worse than death (EQ-5D < 0). All eight
dimension scores were signiﬁcantly correlated (Table 1)
with the EQ-5D, with PF having the strongest relation-
ship (Pearson’s correlation 0.65, P < 0.001).
When grouped by condition (Table 1), the mean
EQ-5D scores ranged from 0.36 for the cohort with
osteoarthritis to 0.79 for the cohort suffering from
chest pain. When using the subgroup mean scores, the
correlations between the health dimensions MH, VT,
GH, and the EQ-5D index were not statistically sig-
niﬁcant (P > 0.05).
Out-of-Sample Data Sets
A total of 22 published studies (Table 2) provided 63
sets of data, which can be used to predict mean EQ-5D
scores using the eight mean health dimension scores.
Eleven studies provided data sets (n = 31) that can be
used to compare incremental scores between two or
more subgroups, and 11 studies provided data sets
(n = 24) that can be used to predict changes over time.
Table 1 Summary statistics of the data sets used in the regressions and the within-sample subgroup validations
Health condition/study
subgroup N Age Mean M %
Mean dimension score
PF SF RP RE MH VT BP GH EQ-5D
Total 6350 51.9 40 67.6 68.2 57.6 67.0 68.3 51.5 63.5 58.7 0.71
Asthma 2730 47.7 40 68.0 64.0 60.1 65.8 67.9 49.6 68.4 53.0 0.74
Chest pain 621 50.3 62 73.5 71.7 49.8 63.8 66.2 50.4 50.4 57.9 0.79
Healthy older women 250 79.6 0 48.1 75.2 42.6 60.5 71.6 51.7 58.3 58.5 0.61
Chronic obstructive
pulmonary disease
94 63.9 53 27.7 48.6 18.6 45.0 66.1 35.0 55.8 31.5 0.54
Menopausal women 681 53.5 0 79.7 81.4 71.5 73.8 67.6 51.8 67.7 65.6 0.77
Irritable bowel syndrome 340 46.5 15 79.9 78.4 66.8 69.7 68.1 51.8 65.0 63.7 0.75
Trauma 151 56.6 60 41.1 50.0 16.3 45.0 61.8 59.1 49.8 69.7 0.57
Lower back pain 126 42.3 37 58.0 62.5 25.0 64.3 68.1 46.3 31.2 62.8 0.54
Leg reconstruction 82 34.3 71 41.6 59.5 38.4 56.9 68.9 54.6 48.2 61.8 0.50
Leg ulcer 232 73.4 34 43.5 66.6 50.5 66.2 69.6 53.3 56.0 64.6 0.56
Osteoarthritis 194 66.8 40 24.4 52.4 12.2 41.2 62.7 58.4 53.2 50.8 0.36
Varicose veins 849 50.4 29 82.7 73.2 75.7 82.6 73.3 57.0 68.7 70.4 0.76
Pearson correlation with
EQ-5D using individual
patient level data
(P < 0.001)
Full data set 6350 0.65 0.57 0.52 0.45 0.45 0.46 0.60 0.49 1
EQ-5D = 0.5 5502 0.60 0.47 0.47 0.37 0.40 0.46 0.57 0.43
EQ-5D < 0.5 848 0.41 0.34 0.38 0.24 0.18 0.25 0.44 0.38
Pearson correlation with
EQ-5D using mean cohort
values (P < 0.001)
0.92 0.74 0.85 0.77 -0.05 0.41 0.58 0.32 1
Bold values not statistically signiﬁcant (P > 0.05).
M, male; PF, physical functioning; SF, social function; RP, role limitations due to physical problems; RE, role limitations due to emotional problems; MH, mental health;VT, vitality; BP,
pain; GH, general health perception.
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Table 2 Summary statistics of the out-of-sample data sets used in validation
Health condition Study arm Time N Age Mean M %
Mean dimension score
PF SF RP RE MH VT BP GH EQ-5D
Renal transplantation S1 Baseline 350 52 59.7 73.1 78.8 61.8 73.8 63.3 71.6 73.7 60.9 0.80
Anderson Fabry S1 Baseline 38 37 100 65.6 57.0 53.9 56.1 41.3 60.7 55.8 37.6 0.56
Hemophilia S1 Baseline 66 38 53.8 70.4 58.1 74.9 55.0 72.9 57.7 46.8 0.66
S2 Baseline 100 46 67.9 79.9 81.2 86.1 61.4 74.0 76.8 64.1 0.85
Stroke S1 Baseline n/a 72 52 19.0 41.0 8.0 48.0 42.0 70.0 64.0 55.0 0.31
S1 6 months 98 67 43.0 62.0 34.0 69.0 52.0 78.0 72.0 59.0 0.62
UA/MI S1 4 months 895 n/a n/a 63.0 73.4 51.7 72.0 52.3 72.4 63.4 59.5 0.748
S1 12 months n/a n/a 62.5 76.9 57.0 74.9 52.9 74.3 65.2 59.4 0.752
S2 4 months 915 n/a n/a 59.3 69.7 44.9 67.1 47.7 70.6 61.7 54.4 0.714
S2 12 months n/a n/a 61.0 72.9 52.4 72.4 50.3 72.5 64.1 55.4 0.736
Claudication S1 Baseline 88 58 72 41.0 67.0 30.0 63.0 54.0 73.0 50.0 56.0 0.57
S1 1 months 84 73.0 76.0 59.0 73.0 63.0 76.0 72.0 61.0 0.79
S1 3 months 84 74.0 80.0 63.0 69.0 65.0 78.0 74.0 60.0 0.77
S1 12 months 72 73.0 83.0 64.0 77.0 61.0 75.0 74.0 58.0 0.75
Depression S1 Baseline 250 44 28 69.0 30.2 22.4 9.1 22.2 24.5 52.0 38.3 0.33
CHD S1 Baseline 78 67 n/a 62.6 73.9 56.8 70.2 61.5 76.7 80.1 53.3 0.69
Lower back pain S1 Baseline 37 50 35 37.3 43.6 14.5 45.2 38.4 59.1 30.1 48.2 0.38
S1 3 months 35 35.1 53.1 12.5 50.0 38.7 61.1 28.6 47.6 0.332
S1 6 months 35 41.5 54.6 20.4 48.1 41.9 62.9 37.0 48.6 0.56
MI S1 1.5 months 229 62 75 60.0 46.6 14.7 42.8 42.9 66.0 66.4 55.5 0.683
S1 12 months 229 63 75 62.9 63.1 46.1 63.4 50.2 71.3 70.6 55.2 0.718
S2 12 months 229 63 100 66.5 64.6 50.6 66.2 52.0 72.6 72.0 55.8 0.735
S3 12 months 229 65 0 49.9 58.2 37.0 53.9 41.8 67.2 65.4 52.5 0.66
Walking impairment S1 Baseline 27 67 78 67.1 0.8 40.2 78.2 32.4 74.1 51.7 76.0 0.66
S2 Baseline 33 67 78 67.1 0.8 42.5 76.9 43.2 74.7 45.3 74.1 0.61
Diabetes S1 Baseline 326 61 56 61.4 0.6 74.4 83.0 52.2 70.9 56.8 78.6 0.81
S2 Baseline 889 66 58 65.7 0.6 48.1 66.6 20.1 50.2 39.1 71.5 0.63
S3 Baseline 1215 65 61 65.1 0.6 45.0 54.0 13.0 34.0 35.5 64.6 0.52
S4 Baseline 65 58 65.5 0.6 23.8 38.7 4.3 17.9 26.7 54.0 0.25
Low back pain S1 Baseline 393 44 49 43.9 0.5 49.1 57.2 25.3 58.9 46.6 64.9 0.48
S2 Baseline 389 43 49 42.8 0.5 45.3 53.4 23.0 49.7 42.1 62.0 0.44
S1 8 months 44.6 0.5 54.1 64.5 37.4 60.7 46.5 65.5 0.56
S2 8 months 43.5 0.5 50.4 58.5 32.9 55.3 40.6 62.3 0.53
S1 24 months 45.9 0.5 56.4 66.4 44.0 61.7 46.2 64.3 0.60
S2 24 months 44.8 0.5 52.8 61.8 38.2 55.8 42.7 62.9 0.54
Hip replacement S1 Baseline 68 38 67.6 0.4 22.0 55.7 11.0 51.7 55.1 73.5 0.35
S1 12 months 69 38 68.6 0.4 60.7 79.2 55.3 68.7 68.4 79.4 0.76
Dry eye S1 Baseline 39 27 39.2 0.3 82.3 91.3 81.6 89.7 66.4 83.6 0.87
S2 Baseline 55 21 55.2 0.2 80.1 85.3 72.3 82.1 56.4 75.5 0.82
S3 Baseline 58 9 58.3 0.1 69.5 67.2 41.7 74.9 44.9 76.4 0.74
Femoral neck fracture S1 Baseline 79 19 79.2 0.2 64.4 77.3 51.0 83.3 65.9 82.1 0.82
S2 Baseline 81 19 80.8 0.2 64.2 78.5 45.2 78.0 61.2 76.5 0.85
S1 4 months 79.2 0.2 49.0 67.6 20.7 54.6 60.0 76.4 0.73
S2 4 months 80.8 0.2 43.5 65.2 23.4 46.8 48.1 68.3 0.60
Pain S1 Baseline 51.8 50 24.3 39.8 0 36.4 29.1 45.8 16.5 40.4 0.08
S2 Baseline 58.4 50 25.5 40.9 0 39.4 28.6 48 14.5 43 0.07
S3 Baseline 51.2 50 29.1 39.3 0 33.2 29.6 43.3 13.1 46.8 0.03
S1 7 days 17.3 40.9 0 36.4 32.3 49.1 22.4 32 0.11
S2 7 days 27.7 52.3 0 54.6 37.7 60.6 34.4 46.9 0.12
S3 7 days 43.2 80.7 0 87.9 58.1 74.5 66.6 45.7 0.61
Hemodialysis S1 Baseline 61.8 56 45.6 60.4 24 56.5 42.7 71.1 59.3 41.6 0.60
S2 Baseline 23 60.2 91 33.4 46.2 15.2 39.1 33.3 62.8 51.4 30 0.45
S3 Baseline 105 62.2 49 48.3 63.6 26 60.3 44.8 73 61.1 42.2 0.65
Psoriasis S1 Baseline 37 49 60 75.7 71.8 76.4 67.6 52.9 67.9 65.3 63 0.72
Liver transplant S1 Baseline 160 53 51 44.19 45.34 13.32 37.78 30 62.06 56.44 31.38 0.53
S1 3 months 160 51.66 63.56 24.27 65.79 47.1 69.83 57.45 57.39 0.62
Focal dystonia S1 Baseline 50 59.2 30 63.6 67.9 53 61.2 54.8 62.2 60.5 47.8 0.59
6 weeks 50 70.8 77.4 63 75.8 63.2 70.9 64.2 51.3 0.66
12 weeks 50 59.6 68.4 49 59.8 53.6 66.4 60.8 48.3 0.63
S2 Baseline 50 59.2 30 73.8 74.4 52.0 75.9 55.6 62.7 55.7 53.2 0.60
6 weeks 50 74.6 83.0 64.0 78.5 64.8 74.6 74.2 52.3 0.76
12 weeks 50 74.2 70.9 46.0 73.2 55.0 59.0 57.5 49.0 0.66
Liver transplant S1 Baseline 51 38 69 78 59 69 55 73 70 66 0.75
Pearson correlation with
EQ-5D (P < 0.001)
0.82 0.85 0.81 0.76 0.79 0.79 0.89 0.61 1
Values assumed when predicting EQ-5D values are 50% male and age = 50 years.
M,male; n/a, not available; PF, physical functioning; SF, social function;RP, role limitations due to physical problems;RE, role limitations due to emotional problems;MH,mental health;
VT, vitality; BP, pain; GH, general health perception; UA, unstable angina; MI, myocardial infarction; CHD, coronary heart disease; S1, study arm 1; S2, study arm 2; S3, study arm 3.
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The studies covered a wide range of health conditions
including Anderson Fabry disease, asthma, coronary
heart disease (CHD), claudication, dialysis, depres-
sion, diabetes, dry eye, femoral neck fracture, focal
dystonia, hemophilia, hip replacements, liver trans-
plant, lower back pain, osteoporosis, pain, psoriasis,
renal transplantation, stroke, and walking impair-
ment. Further details of the studies are available from
the authors on request.
The mean EQ-5D scores ranged from 0.03 for a
cohort (n = 11) with central neuropathic pain to 0.87
for a cohort (n = 48) with dry eye. The incremental
difference between different cohorts within the same
study ranged from 0.01 for individuals enrolled in
randomized controlled trials (RCTs) to 0.56 for dia-
betics subgrouped by self-assessed using the neuro-
pathy total symptom scores (six domains).
Goodness of Fit and Accuracy of Models
Table 3 shows the results of the individual regression
analyses using the eight health dimension scores and
their squares. The explanatory power of the model
using just the eight main effects (EQ [1]) was 56%, and
theMAE andRMSE for the individual predictions were
0.134 and 0.183, respectively. The eight main effects
were all statistically signiﬁcant (P < 0.05) predictors.
While the majority of the coefﬁcients are positive, dem-
onstrating the positive relationship with HRQoL, the
coefﬁcients for the RP and VT variables are negative.
Although this might suggest colinearity with other vari-
ables, the VIFs were small at 2.34 and 2.39.
Plotting the residuals, observed and predicted
EQ-5D data (Fig. 1) show that model EQ (1) under-
predicts at higher levels of utility and overpredicts at
lower levels as is commonly seen in HRQoL regres-
sions. The Cook–Weisberg test (c2 = 2445, P < 0.001)
suggest the residuals are heteroscedastic while the
larger errors at the lower end of the utility scale (Fig. 1)
show the variance in the residuals are not normally
distributed (Shapiro–Wilk test z = 13, P < 0.0001).
Looking at the observed maximum EQ-5D (24% = 1)
data points, the ME in the predicted values was 0.10
(range -0.5 to 0.70) with 551 (31%) of values under-
predicted by at least 0.1. Conversely, looking at the
lower quartile (EQ-5D = 0.62), the ME in the pre-
dicted values was -0.14 (range -1.16 to 0.43) with
834 (55%) of values overpredicted by at least 0.1.
While sex was not statistically signiﬁcant (not
shown), the inclusion of age as a predictor (model EQ
[2]) has little impact on the explanatory power of the
model (56%), the MEs, or the accuracy of the pre-
dicted values. Removing the variables RP and VT also
has little impact on the explanatory power or accuracy
of the predicted values (model EQ [3]). When includ-
ing the statistically signiﬁcant squared dimension
scores (PF, SF, MH, and BP), the explanatory power
increases slightly to 58.5% (models EQ [4] and EQ
[5]). The MAE and RMSE for both models were 0.131
and 0.178, respectively. The inclusion of the variable
age squared as a predictor in addition to signiﬁcant
squared dimension terms (models EQ [6] and EQ [7])
produced models with the highest explanatory power
(>58.6%), and smallest MAEs and RMSEs (0.1299
and 0.178, respectively).
When including the signiﬁcant squared dimension
scores, models EQ (4) and EQ (5) predicted the total
mean value for the individual level data correct to
three decimal places as opposed to two decimal places
for the other models. The range (min – 0.21 to max
0.997) for the models (EQ [4] to EQ [7]) that include
the squared terms was larger than the range (min
0.033 to max 1.059) for the models (EQ [1] to EQ [3])
that do not include the squared terms. The variance in
the individual predicted scores was underestimated by
all the models with standard deviations ranging from
0.208 (EQ [1] to EQ [3]) to 0.212 (EQ [4] to EQ [7])
in comparison to 0.277 in the observed values.
The relationships between the actual and predicted
EQ-5D scores for models EQ (1), EQ (4) and EQ (7)
are shown in Fig. 2. Models EQ (4) and EQ (7) gen-
erate more negative values than model EQ (1), so the
variance in the errors is greater.
Accuracy UsingWithin-Sample Mean Statistics
The primary objective of the study was to predict the
mean preference-based EQ-5D utility scores using
reported mean dimension scores derived from the
responses to the SF-36 questionnaire. Using the mean
values from the eight dimension scores to predict the
mean EQ-5D score for the full data set (Table 4),
models EQ (1), EQ (2), and EQ (3) were much more
accurate with MEs of 0.001, than models EQ (4) to
EQ (7), which produce MEs greater than 0.067. When
subgrouped by health condition, the ME (MAE and
RMSE) in the 12 predicted values were approximately
0.021 (0.045 and 0.056) for models EQ (1) to EQ (3)
compared with 0.076 (0.082 and 0.093) for models
EQ (4) to EQ (7). These statistics show that the models
that include the squared terms tend to overpredict
the mean values. Models EQ (1) to EQ (3) predicted
between 62% and 69% of the scores to within |0.05| as
opposed to between 15% and 31% for models EQ (5)
and EQ (7), respectively. Model EQ (3) has the largest
proportion (54%) of predicted values with errors
smaller than |0.025|. Model EQ (1) predicted 85% of
values to within the MID of 0.074.
Accuracy Using Out-of-Sample Mean Statistics
When assessing the models’ accuracy in predicting the
out-of-sample mean EQ-5D scores using summary sta-
tistics (Table 5), of the 63 predicted scores, the models
with the squared terms (models EQ [4] to EQ [7])
produced larger MEs greater than 0.097 as opposed to
below 0.05 for the models that do not include the
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squared terms. There is little to choose between the
MAE for models EQ (1), EQ (2), and EQ (3) at
0.0641, 0.0654, and 0.0654, respectively. Models EQ
(4) to EQ (7) were less accurate with an MAE greater
than 0.098. Approximately 62% (37%) of the scores
for models EQ (1) to EQ (3) were correct to within
|0.05| (|0.025|) compared with 30% (8%) of the scores
for models EQ (4) to EQ (7) (Table 5 and Fig. 3).
Model EQ (2) has the greatest proportion (78%)
correct to within the MID.
A histogram (Fig. 3) of the distribution of the errors
in the predicted out-of sample mean EQ-5D scores for
models EQ (1) and EQ (4) shows that model EQ (1) has
a large proportion of values (29%) that are identical to
the actual value. Model EQ (1) has a substantial pro-
portion (48%) that are within 5% of the actual value.
When comparing how accurate the models are
when predicting incremental differences between study
arms (n = 31), all the models produced an ME smaller
than 0.0023 (Table 6) and approximately 70% of
values were accurate to within |0.05|. Almost 50% of
the incremental values were also accurate to within
|0.025| and more than 77% were accurate to within
the MID. When looking at the incremental changes
over time (Table 7), the models that include the
squared terms (EQ [4] to EQ [7]) produced the small-
est errors. The MEs for models EQ (4) to EQ (7) were
approximately 0.027 compared with approximately
0.034 for models EQ (1) to EQ (3). Sixty-seven percent
(46%) of incremental changes over time were correct
to within |0.05| (|0.025|) for models EQ (4) to EQ (7)
compared with 63% (<42%) for models EQ (1) to EQ
(3). Models EQ (1) to EQ (3) predicted 83% of
changes to within the MID.
Overall, when comparing the errors in the out-of
sample predicted mean EQ-5D scores, model EQ (1)
was themost accurate. Looking at Fig. 4a, which shows
the actual out-of-sample mean EQ-5D scores, the pre-
dicted values and errors for model EQ (1), it can be seen
that the model overpredicts the lower EQ-5D scores
and there is a trend for the errors to increase in magni-
tude as the mean EQ-5D score decreases. When assess-
ing the accuracy in predicting incremental values, i.e.,
differences between study arms and changes over time,
model EQ (4) was themost accurate overall. Looking at
Fig. 4b, there is a tendencyfor the errors in the predicted
-1.0
-0.5
0.0
0.5
1.0
Actual EQ-5D EQ(1) predicted values EQ(1) residual
Figure 1 Residuals, observed and predicted
EQ-5D values for model EQ (1).
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Figure 2 Plot of the predicted (models EQ
[1], EQ [4], and EQ [7]) against actual EQ-5D
scores.
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incremental values to increase in magnitude as the
difference in the scores increases.
Applying the Algorithm
An illustration of how the algorithms are applied is
provided below using the summary statistics for the
liver transplant cohort (Table 2) and model EQ (1).
EQ-5D PF SF
RP RE
= + × + × −
× + × +
0 03256 0 0037 0 0011
0 00024 0 00024 0
. . .
. . .00256
0 00063 0 00286
0 00052
×
− × + × +
×
MH VT BP
GH
. .
.
EQ-5D = + × + ×
− × + × +
0 03256 0 0037 69 0 00111
0
78 0 00024 59 0 00024 69
. . .
. .
. .
. .
00256 55 0 00063 73
0 000286 70 0 00052 66
× − × +
× + ×
EQ-5D = 0 706.
This gives an estimate EQ-5D score of 0.706 compared
with the actual value of 0.750.
Discussion
The SF-36 is one of the most widely used HRQoL
instruments, but because the SF-6D is a comparatively
new measure, a substantial proportion of the SF-36-
based research is presented in terms of a health proﬁle
using the mean values of the eight dimension scores.
Because the number of preference-based instruments
continues to grow, if the results of economic evalua-
tions are to be compared effectively, it will become
increasingly important to be able to translate between
the different QoL measures used. The models pre-
Table 5 Errors in the predicted out-of-sample mean EQ-5D scores (n = 63)
Model ME MAE RMSE <|0.05| (%) <|0.025| (%) <|0.01| (%) <MID (%)
EQ (1) 0.0498 0.0641 0.1011 63 37 14 76
EQ (2) 0.0495 0.0654 0.1024 62 37 11 78
EQ (3) 0.0476 0.0654 0.1016 62 35 11 75
EQ (4) 0.0980 0.0988 0.1234 30 10 2 44
EQ (5) 0.0972 0.0981 0.1228 29 8 2 44
EQ (6) 0.0979 0.0989 0.1236 30 8 2 44
EQ (7) 0.0987 0.0995 0.1241 30 8 2 44
ME, mean error; MAE, mean absolute error; RMSE, root mean squared error; MID, minimal important difference.
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Figure 3 Distribution of the errors in the pre-
dicted out-of-sample mean EQ-5D scores.
Table 6 Incremental differences of mean EQ-5D scores between study arms (n = 31)
Model ME MAE RMSE <|0.05| (%) <|0.025| (%) <|0.01| (%) <MID (%)
EQ (1) -0.0007 0.0498 0.0774 71 45 26 81
EQ (2) 0.0002 0.0506 0.0774 71 42 19 77
EQ (3) 0.0014 0.0524 0.0798 71 45 19 77
EQ (4) -0.0019 0.0441 0.0685 68 48 29 81
EQ (5) -0.0023 0.0440 0.0685 71 45 26 81
EQ (6) -0.0021 0.0441 0.0685 71 45 26 81
EQ (7) -0.0016 0.0441 0.0684 71 45 29 81
ME, mean error; MAE, mean absolute error; RMSE, root mean squared error; MID, minimal important difference.
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sented here offer two substantial beneﬁts: ﬁrst, they
provide a mechanism to obtain preference-based utility
scores from published nonpreference-based QoL data,
and second, they provide analysts with a methodology
to map between two of the most frequently used
HRQoL instruments.
The OLS models presented here explain more than
56% of the variance in the EQ-5D scores. These are
comparable with the results (63% [19], 58% [17], and
58% [20]) obtained when mapping the SF-12
summary scores onto the UK-based EQ-5D preference-
based utility index using OLS regressions. Sullivan
et al. reported values of 58% for an OLS model and
92% for a Tobit model involving 18 independent vari-
ables including the SF-12 summary scores and socio-
demographic variables, such as ethnicity and
education, when mapping onto the US preference-
based EQ-5D index [21]. Nichol et al. used the OLS
regressions to derive a model that explained 51% of
variance in the HUI2 using age, sex, and the eight
dimension scores obtained from the SF-36 responses
(n = 6921) as the independent variables [10]. The
reported variance explained in the models mapping
from the SF-36 eight dimension scores to the HUI
indexes range from 37% [11] to 53% [13].
The results of this study are also comparable with
the published evidence when assessing the residuals in
the predicted scores. The MAEs for our models ranged
from 0.130 to 0.1340 for the individual predictions,
from 0.045 to 0.083 for the within-sample subgroup
Table 7 Incremental changes of mean EQ-5D scores over time (n = 24)
Model ME MAE RMSE <|0.05| (%) <|0.025| (%) <|0.01| (%) <MID (%)
EQ (1) 0.0335 0.0527 0.0788 63 42 21 83
EQ (2) 0.0344 0.0531 0.0793 63 38 21 83
EQ (3) 0.0342 0.0532 0.0801 63 38 21 83
EQ (4) 0.0265 0.0480 0.0677 67 46 21 75
EQ (5) 0.0267 0.0484 0.0681 67 46 21 75
EQ (6) 0.0268 0.0486 0.0682 67 46 25 71
EQ (7) 0.0265 0.0482 0.0678 67 46 21 75
ME, mean error; MAE, mean absolute error; RMSE, root mean squared error; MID, minimal important difference.
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Figure 4 (a) Actual out-of-sample mean
EQ-5D scores, predicted values and errors for
model EQ (1). (b) Incremental out-of-sample
EQ-5D scores, predicted incremental values
and errors for model EQ (4).
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analyses and from 0.0641 to 0.099 for the out-of-
sample scores. Sullivan et al. reported MAEs for the
individual US weighted predictions ranging from
0.0726 for a censored least absolute deviations
(CLAD) model to 0.0765 for a Tobit model [21].
Franks et al. reported an MAE ranging from 0.381 for
EQ-5D scores smaller than 0 to 0.070 for EQ-5D
scores greater than 0.9 [19]. Gray et al. reported an
MAE of 0.108 for within sample predictions and
0.115 for out-of-sample predictions when presenting
the results of a study mapping responses in SF-12 data
to EQ-5D responses [22].
While several of the published studies validated
results using out-of-sample data sets, to our knowl-
edge, this is the ﬁrst study which uses published data
sets to predict mean preference-based utility scores
using mean cohort scores for the independent vari-
ables. The errors observed at the individual level still
exist when applying the algorithms to summary data,
but the magnitude of the errors is much smaller. When
using model EQ (2), 49 (78%) of the 63 predicted
out-of-sample mean EQ-5D scores were accurate to
within |0.074| the established MID for the EQ-5D
[37]. We are also the ﬁrst to report in terms of accuracy
when predicting incremental values. Looking at the
differences between the study cohorts, 25 (81%) of
the 31 predicted values for Model EQ 1) were within
the MID. Looking at changes over time, 20 (83%)
of the 24 predicted values for models EQ (1), (2), and
(3) are within the MID.
The maximum range (1.206) in the predicted indi-
vidual EQ-5D scores is obtained from model EQ (7),
while the minimum range (1.004) is obtained from
model EQ (3). These cover 76% and 64% of the actual
EQ-5D index (-0.594 to 1.0), respectively. Using ages
of 18 and 99 years, the largest possible range is 1.331
(-0.296 to 1.034) using model EQ (6), while the small-
est range is 1.047 (0.023–1.070) using model EQ (3).
When subgrouping the out-of-sample data sets by
actual EQ-5D score; 15 (24%) of 63 have scores
greater than 0.70 and smaller than 0.80, while 7
(11%) of 63 have scores greater than or equal to 0.80.
The MEs (MAE) in the predicted values for these sub-
groups when using model EQ (1) were -0.001 (0.021)
and -0.022 (0.028), respectively. Between 87% and
100% of values for these subgroups were within the
MID irrespective of the model used.
Looking at the out-of-sample data sets at the
lower end of the EQ-5D scale, ﬁve cohorts have a
mean EQ-5D score smaller than or equal to 0.175,
and ﬁve cohorts have a mean EQ-5D score greater
than 0.175 and smaller than 0.35. The MEs in the
predicted values for these two subgroups when using
model EQ (1) are 0.285 and 0.158, respectively. The
magnitude of the errors in predicted values for the
cohorts with very low EQ-5D scores was problem-
atic. The models produced estimates that are
regressed to the mean, and this is exacerbated
because the distribution of the EQ-5D scores in the
data set used in the regressions was skewed with a
comparatively small proportion (848 of 6350) of
individuals scoring below 0.5. In addition, the rela-
tionships between the EQ-5D values and the dimen-
sion scores were weaker for the data points at the
lower end of the index (Table 1). Caution should be
taken when applying the algorithms to data sets
likely to have very low utility values. Further research
involving a greater proportion of individuals with
severely impaired health states is required to deter-
mine whether separate models for cohorts with very
low HRQoL would be beneﬁcial.
Literature describing the relationships between the
EQ-5D index and the two SF-12 summary scores
continues to grow. Nevertheless, to our knowledge,
there is no published methodology that can be used to
convert reported mean dimension scores from the full
health proﬁle of the SF-36 into an EQ-5D utility score.
It is possible that the use of the eight dimension scores,
as opposed to the two overall scores, could produce
an algorithm with the ability to describe smaller dif-
ferences and changes. Nevertheless, further research is
required to conﬁrm this.
There is no evidence that sex adds to the variance
explained by the models. The results suggest that the
dimension scores RP and VT add little to either the
goodness of ﬁt or the accuracy of the scores gener-
ated by the models. This probably reﬂects the fact
that EQ-5D does not contain a VT domain. Likewise,
while the inclusion of the signiﬁcant squared terms
increases the variance explained by the model
slightly, the predictions for the out-of-sample values
are less accurate. Overall, there is very little to choose
between the goodness of ﬁt and the accuracy of the
predictions generated by the models presented here.
Based on the out-of-sample validations, we advocate
model EQ (1) as the ﬁrst choice for predicting mean
EQ-5D scores from mean dimension SF-36 scores
when patient level data are not available. Neverthe-
less, when comparing incremental differences be-
tween study arms or changes over time, model EQ
(4) is the preferred choice.
In conclusion, we have found that the results of a
simple OLS regression can be used to transform the
mean dimension scores from the SF-36 questionnaire
into mean preference-based EQ-5D scores. The model
is reasonably accurate when predicting out-of-sample
data including absolute values, incremental changes
between study arms, and incremental changes over
time. The results suggest that the algorithm could be
used to populate health states in economic models
when EQ-5D data is not available. Nevertheless,
mapping is always second best to either using the
EQ-5D directly in clinical studies or to obtaining pref-
erence weights for the nonpreference measure where
Estimating a Mean EQ-5D Score from the SF-36 1141
the EQ-5D is not appropriate for the condition.
Further research is required to reﬁne and improve on
the models presented here.
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